Benzyl Caffeate

Benzyl Caffeate

SCHEMBL1877243

O=C(/C=C/c1ccc(O)c(O)c1)OCc1ccccc1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKR1B10 O60218 4/20 1.00
AKR1B1 P15121 4/20 1.00
TTR P02766 4/20 1.00
APP P05067 9/20 0.76
CYP3A4 P08684 2/20 0.76
ALOX15 P16050 2/20 0.76
ALOX12 P18054 2/20 0.76
MAPK1 P28482 2/20 0.76
HSD17B10 Q99714 2/20 0.76
LMNA P02545 2/20 0.76
KDM4E B2RXH2 1/20 0.76
MEN1 O00255 1/20 0.76
GMNN O75496 1/20 0.76
ALDH1A1 P00352 1/20 0.76
EGFR P00533 1/20 0.76
ESR1 P03372 1/20 0.76
ERBB2 P04626 1/20 0.76
LCK P06239 1/20 0.76
FYN P06241 1/20 0.76
ALOX5 P09917 1/20 0.76

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Benzyl Caffeate SCHEMBL1659796 1.00 AKR1B10 (1.00) AKR1B10AKR1B1TTRAPPCYP3A4
SCHEMBL25647016 0.89 TTR (0.81) AKR1B10AKR1B1TTRAPPCYP3A4
SCHEMBL19163944 0.88 AKR1B10 (0.78) AKR1B10AKR1B1TTRAPPCYP3A4
SCHEMBL13552179 0.86 LMNA (0.93) AKR1B10AKR1B1TTRAPPCYP3A4
SCHEMBL26932236 0.86 TTR (0.76) AKR1B10AKR1B1TTRAPPCYP3A4
SCHEMBL30683157 0.86 TTR (0.76) AKR1B10AKR1B1TTRAPPCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL28294426 0.86 AKR1B10 (1.00) AKR1B10AKR1B1TTRAPPCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL30070826 0.86 AKR1B10 (1.00) AKR1B10AKR1B1TTRAPPCYP3A4
SCHEMBL28537490 0.86 TTR (0.76) AKR1B10AKR1B1TTRAPPCYP3A4
Caffeic Acid Phenethyl Ester SCHEMBL93649 0.86 AKR1B10 (1.00) AKR1B10AKR1B1TTRAPPCYP3A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117402197-B Vitex negundo extract and preparation method thereof and identification method of Vitex negundo honey 江苏蜂奥生物科技有限公司 2026-05-15 CN claimed
CN-117402197-A Vitex negundo extract and preparation method thereof and identification method of Vitex negundo honey 江苏蜂奥生物科技有限公司 2024-01-16 CN claimed
EP-3423429-B1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY UNIV DE MONCTON (CA) 2023-07-12 EP claimed
CN-105307665-B Therapeutic compositions and uses thereof 蜜纽康新西兰有限公司 2021-09-28 CN claimed
CN-104592188-B A kind of isolated and purified pinobanksin and method of caffeinic derivant from China's Water extracts of propolis 聊城大学 2016-08-24 CN claimed
US-20150274633-A2 PAIN RELIEF COMPOUNDS UNIVERSITÉ CLERMONT AUVERGNE (FR) 2015-10-01 US claimed
US-20150038466-A1 PAIN RELIEF COMPOUNDS ECOLE NATIONALE SUPERIEURE DE CHIMIE DE CLERMONT FERRAND (FR) 2015-02-05 US claimed
US-12605352-B2 Compositions and methods for inhibiting blood cancer cell growth THE UNIVERSITY OF NEW BRUNSWICK (CA) 2026-04-21 US disclosed
US-20240425441-A9 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY ICOSA PHARMA INC. (CA) 2024-12-26 US disclosed
WO-2024136261-A1 ANTI-INFLAMMATORY OR ANTIOXIDANT COMPOSITION COMPRISING BENZYL CAFFEATE AS ACTIVE INGREDIENT 동아대학교 산학협력단 2024-06-27 WO disclosed
US-20230391711-A1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY UNIV DE MONCTON (CA) 2023-12-07 US disclosed
EP-4276089-A2 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY Universite De Moncton (CA) 2023-11-15 EP disclosed
EP-4276089-A2 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY Universite De Moncton (CA) 2023-11-15 EP disclosed
US-20100152143-A1 Methods of Treating Skin Disorders with Caffeic Acid Analogs MOLECULIN, LLC (US) 2010-06-17 US disclosed
US-7700642-B2 Process for producing an aromatic unsaturated compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-04-20 US disclosed
US-20090111999-A1 PROCESS FOR PRODUCING AN AROMATIC UNSATURATED COMPOUND SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-04-30 US disclosed
US-20080221337-A1 Process for Producing an Aromatic Unsaturated Compound SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2008-09-11 US disclosed
US-20080167277-A1 METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS MOLECULIN, L.L.C. 2008-07-10 US disclosed
US-20080167277-A1 METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS MOLECULIN, L.L.C. 2008-07-10 US disclosed
EP-1666440-A1 METHOD FOR PRODUCING AROMATIC UNSATURATED COMPOUND Sumitomo Chemical Company, Limited (JP) 2006-06-07 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100152143-A1 Methods of Treating Skin Disorders with Caffeic Acid Analogs CUTA, TYR, PPARA AKR1B10 1463/4885AKR1B1 1210/4885TTR 2325/4885
US-20080167277-A1 METHODS OF TREATING SKIN DISORDERS WITH CAFFEIC ACID ANALOGS CYP24A1, VDR, CYP2R1 AKR1B10 2192/4885AKR1B1 1890/4885TTR 2718/4885
US-20240425441-A9 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY ALOX12, ALOX15B, ALOX5 AKR1B10 392/4885AKR1B1 182/4885TTR 3270/4885
US-20080221337-A1 Process for Producing an Aromatic Unsaturated Compound AHR, AR, ARSA AKR1B10 74/4885AKR1B1 44/4885TTR 3961/4885
US-20230391711-A1 MODULATORS OF LIPOXYGENASE AND CYCLOOXYGENASE ENZYME ACTIVITY ALOX12, ALOX15B, ALOX5 AKR1B10 392/4885AKR1B1 182/4885TTR 3270/4885
US-20150038466-A1 PAIN RELIEF COMPOUNDS OPRL1, OPRK1, TRPV1 AKR1B10 1601/4885AKR1B1 1390/4885TTR 1663/4885
US-20150274633-A2 PAIN RELIEF COMPOUNDS OPRL1, OPRK1, TRPV1 AKR1B10 1601/4885AKR1B1 1390/4885TTR 1663/4885
US-20090111999-A1 PROCESS FOR PRODUCING AN AROMATIC UNSATURATED COMPOUND AHR, AR, ARSA AKR1B10 74/4885AKR1B1 44/4885TTR 3961/4885
US-12605352-B2 Compositions and methods for inhibiting blood cancer cell growth MCL1, HRH2, SLC25A11 AKR1B10 2410/4885AKR1B1 2335/4885TTR 1978/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.